Ultrasound

Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.

Catch up on the most-well viewed radiology content in January 2025.

Designed for advanced OB-GYN applications, the Samsung Z20 ultrasound platform reportedly provides a combination of artificial intelligence (AI) tools and enhanced ergonomics.

An array of AI-powered features and automated tools may lead to improved workflow and image quality with the Voluson Expert 22, 20 and 18 ultrasound systems.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the top radiology content of the past week.

For patients previously assessed with LI-RADS LR-4 and LR-M presentations based on MRI or CT findings, the use of contrast-enhanced ultrasound led to 30 percent of these patients having LR-5 assessments definitive for hepatocellular carcinoma.

The latest ultrasound software update from Clarius includes new artificial intelligence (AI) capabilities, coding assistance and a variety of advances tailored to different fields of medicine.

Catch up on the top radiology content of the past week.

Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in 2024.

Catch up on the most viewed content on AI in radiology from 2024.

Catch up on the most well-viewed prostate imaging content from 2024.

Catch up on the most well-read ultrasound content from 2024.

Catch up on the most well-read mammography articles from 2024.

Do we get mired in the rut of generational grumbling, or do we reframe resentments into perspective of what we have overcome?

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the top radiology content of the past week.

The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.

Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.

Reportedly developed on over 90,000 ultrasound exams, the BrightHeart AI software identifies suspicious findings suggestive of congenital heart defects through AI-powered evaluation of fetal heart morphology.

Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.

Catch up on the top radiology content of the past week.

Catch up on the most-well viewed radiology content in October 2024.

Catch up on the top radiology content of the past week.

The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.

The new ultrasound platform reportedly offers a combination of enhanced imaging and AI-enabled tools to facilitate improved workflow efficiency.

Catch up on the top radiology content of the past week.

In a multicenter study of over 370 women who had surgery for ovarian cystic lesions without acute symptoms, researchers found that 42 percent of the resected lesions were deemed to have an O-RADS ultrasound risk score of 2, which has less than a one percent chance of malignancy.

With the capability of identifying possible cases of aortic value stenosis (AVS) from existing electrocardiograms (ECGs), the AI-powered screening software from AccurKardia may facilitate earlier diagnosis of AVS, which is fatally missed in 50 percent of patient who have this condition.